Pharmacological effects, molecular mechanisms and strategies to improve bioavailability of curcumin in the treatment of neurodegenerative diseases

With the global population aging, the incidence of neurodegenerative diseases (NDs), such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis, has been progressively increasing. However, effective therapeutic strategies and clinical drugs for these dis...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 16; p. 1625821
Main Authors Wang, Gang, Zhou, Xueyuan, Pang, Xiaoyan, Ma, Ke, Li, Lu, Song, Yuexin, Hou, Dongxia, Wang, Xiaohua
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 10.07.2025
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:With the global population aging, the incidence of neurodegenerative diseases (NDs), such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis, has been progressively increasing. However, effective therapeutic strategies and clinical drugs for these disorders remain scarce. Curcumin, a natural polyphenolic compound primarily derived from the herbaceous plant Curcuma longa L., has been proposed as a promising candidate for ND treatment based on the excellent antioxidant, anti-inflammatory and neuroprotective properties. Its pharmacological activities encompass scavenging reactive oxygen species, mitigating toxic protein aggregation and cytotoxicity, repairing mitochondrial dysfunction, and inhibiting excessive neuronal apoptosis. Compared with synthetic drugs, curcumin demonstrates a more favorable safety profile with fewer side effects. Nevertheless, its clinical application is substantially hindered by poor bioavailability, which stems from low aqueous solubility, inefficient intestinal absorption, and rapid metabolism and systemic elimination. Conventional administration methods often fail to achieve effective concentrations in vivo . Further clinical trials are also required to validate the therapeutic efficacy and potential adverse effects in human subjects. This article systematically reviews the pathogenesis of NDs and the knowledge on curcumin including pharmacological effects, neuroprotective mechanisms, functions across specific NDs and advanced strategies to enhance the bioavailability, with the aim of promoting the development and clinical translation of curcumin-based therapeutics for NDs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Mahmood Ahmed, University of Education Lahore, Pakistan
Limamanen Phom, Sao Chang College, India
Tapan A. Patel, University of Nebraska Medical Center, United States
Edited by: Paul Chazot, Durham University, United Kingdom
These authors have contributed equally to this work
Reviewed by: Venkata Ramireddy Narala, Yogi Vemana University, India
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2025.1625821